Alliance for Pandemic Preparedness

May 26, 2021

Monoclonal Antibody Treatment Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread

Category:

Topic:

Keywords (Tags): , , ,

  • [Pre-print, not peer-reviewed] A modeling study of SARS-CoV-2 transmission in the US population found that allocating monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP) and treatment of persons with COVID-19 in combination with a vaccination program could substantially reduce infections and mortality. Allocation of mAbs as PEP to persons >65 years of age averted up to 17% of infections and 41% of SARS-CoV-2 associated deaths relative to vaccine alone. The authors suggest that the benefits of mAbs for early treatment and PEP could be enhanced in scenarios where rapid vaccine deployment is not feasible.  

Kamal et al. (May 25, 2021). Monoclonal Antibody Treatment Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread. Pre-print downloaded May 26 from https://doi.org/10.1101/2021.05.21.21257624